A Phase 1, Open-label, Dose-escalation Study of SNX 5422 and Everolimus in Subjects With Neuroendocrine Tumors.

Trial Profile

A Phase 1, Open-label, Dose-escalation Study of SNX 5422 and Everolimus in Subjects With Neuroendocrine Tumors.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs SNX 5422 (Primary) ; Everolimus
  • Indications Neuroendocrine tumours
  • Focus Adverse reactions
  • Sponsors Esanex
  • Most Recent Events

    • 25 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Oct 2017.
    • 25 Apr 2017 Planned End Date changed from 1 Apr 2017 to 1 Jun 2017.
    • 18 Nov 2016 Planned End Date changed from 1 Feb 2017 to 1 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top